ARCHIVES

Docetaxel As Adjuvant Therapy Shows Benefit Over Standard

This article is from The Cancer Letter archive.

Vol. 25 No. 6 | June 28, 2002

Download PDF Visit The Full Archive

Related Articles

Rall Says NTP Must Have New Positions To Spend Extra $23 Million On Testing More Chemicals

September 7, 1979

BRMP Workshops Planned; DCT Board Balk At Size of Intramural Budget

November 28, 1980

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

April 27, 2012

Upton Says NCI Must Take “Vigorous Role” In Prevention

February 3, 1978

Targeting Men At High Risk Finds More Head & Neck Cancer

September 24, 2010

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

May 18, 2007